Xeljanz vs. Rinvoq

Reviewed on 9/22/2020

Are Xeljanz and Rinvoq the Same Thing?

Xeljanz (tofacitinib citrate) and Rinvoq (upadacitinib) are Janus kinase (JAK) inhibitors used to treat adults with moderate to severely active rheumatoid arthritis (RA) who have not responded well to methotrexate, or cannot tolerate it.

Side effects of Xeljanz and Rinvoq that are similar include upper respiratory tract infections.

Side effects of Xeljanz that are different from Rinvoq include headache, diarrhea, and cold symptoms such as sore throat, runny or stuffy nose.

Side effects of Rinvoq that are different from Xeljanz include nausea, cough, and fever.

Xeljanz may interact with aprepitant, bosentan, conivaptan, haloperidol, imatinib, isoniazid, St. John's wort, ticlopidine, antibiotics, antidepressants, antifungals, hepatitis C medications boceprevir or telaprevir, heart or blood pressure medicines, HIV or AIDS medicines, medications to treat excess stomach acid, medicines to prevent organ transplant rejection, nonsteroidal anti-inflammatory drugs (NSAIDs), other arthritis medications, seizure medications, and steroids.

Rinvoq may interact with strong CYP3A4 inhibitors (e.g., ketoconazole), strong CYP3A4 inducers (e.g., rifampin), and live vaccines.

What Are Possible Side Effects of Xeljanz?

Side effects of Xeljanz include:

Common side effects of Xeljanz include:

  • upper respiratory tract infections,
  • headache,
  • diarrhea, and
  • cold symptoms such as sore throat, runny or stuffy nose.

Tell your doctor if you experience serious side effects of Xeljanz including:

What Are Possible Side Effects of Rinvoq?

Common side effects of Rinvoq include:

  • upper respiratory tract infections,
  • nausea,
  • cough, and
  • fever

QUESTION

The term arthritis refers to stiffness in the joints. See Answer

What Is Xeljanz?

Xeljanz (tofacitinib citrate) is a Janus kinase (JAK) inhibitor used to treat adults with moderate to severely active rheumatoid arthritis (RA) who have not responded well to methotrexate, or cannot tolerate it.

What Is Rinvoq?

Rinvoq (upadacitinib) is a Janus kinase (JAK) inhibitor indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.

What Drugs Interact With Xeljanz?

Xeljanz may interact with aprepitant, bosentan, conivaptan, haloperidol, imatinib, isoniazid, St. John's wort, ticlopidine, antibiotics, antidepressants, antifungals, hepatitis C medications boceprevir or telaprevir, heart or blood pressure medicines, HIV or AIDS medicines, medications to treat excess stomach acid, medicines to prevent organ transplant rejection, nonsteroidal anti-inflammatory drugs (NSAIDs), other arthritis medications, seizure medications, or steroids. Tell your doctor all medications and supplements you use.

What Drugs Interact With Rinvoq?

Rinvoq may interact with strong CYP3A4 inhibitors (e.g., ketoconazole), strong CYP3A4 inducers (e.g., rifampin), and live vaccines. Tell your doctor all medications and supplements you use. Rinvoq is not recommended for use during pregnancy; it may harm a fetus. Females of reproductive potential are advised to use effective contraception during treatment with Rinvoq and for 4 weeks following completion of therapy. It is unknown if Rinvoq passes into breast milk. Because of the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended during treatment with Rinvoq, and for 6 days after the last dose.

How Should Xeljanz be Taken?

The recommended dose of Xeljanz is 5 mg twice daily.

How Should Rinvoq be Taken?

The recommended dose of Rinvoq is 15 mg once daily. Rinvoq may be used as monotherapy or in combination with methotrexate or other nonbiologic DMARDs.

SLIDESHOW

What Is Rheumatoid Arthritis (RA)? Symptoms, Treatment, Diagnosis See Slideshow
Disclaimer

All drug information provided on RxList.com is sourced directly from drug monographs published by the U.S. Food and Drug Administration (FDA).

Any drug information published on RxList.com regarding general drug information, drug side effects, drug usage, dosage, and more are sourced from the original drug documentation found in its FDA drug monograph.

Drug information found in the drug comparisons published on RxList.com is primarily sourced from the FDA drug information. The drug comparison information found in this article does not contain any data from clinical trials with human participants or animals performed by any of the drug manufacturers comparing the drugs.

The drug comparisons information provided does not cover every potential use, warning, drug interaction, side effect, or adverse or allergic reaction. RxList.com assumes no responsibility for any healthcare administered to a person based on the information found on this site.

As drug information can and will change at any time, RxList.com makes every effort to update its drug information. Due to the time-sensitive nature of drug information, RxList.com makes no guarantees that the information provided is the most current.

Any missing drug warnings or information does not in any way guarantee the safety, effectiveness, or the lack of adverse effects of any drug. The drug information provided is intended for reference only and should not be used as a substitute for medical advice.

If you have specific questions regarding a drug’s safety, side effects, usage, warnings, etc., you should contact your doctor or pharmacist, or refer to the individual drug monograph details found on the FDA.gov or RxList.com websites for more information.

You may also report negative side effects of prescription drugs to the FDA by visiting the FDA MedWatch website or calling 1-800-FDA-1088.

References
Pfizer. Xeljanz Product Monograph.

https://www.xeljanz.com

FDA. Rinvoq Product Information.

https://www.rinvoq.com

Health Solutions From Our Sponsors